Acadia Healthcare Appoints Todd Young as Chief Financial Officer, Strengthening Leadership Team for Next Phase of Growth
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (“Acadia” or the “Company”) announced today the appointment of Todd Young as its new Chief Financial Officer (CFO), effective October 27, 2025. Young succeeds Tim Sides, who has served as interim CFO since August 2025 and will now return to his previous role as Senior Vice President, Operations Finance. The leadership transition marks a strategic move by Acadia as it continues to refine its operational and financial infrastructure to support its mission of expanding access to high-quality behavioral health and addiction treatment services across the United States.
Young brings to Acadia nearly a decade of senior-level financial leadership experience within the publicly traded healthcare sector. His appointment underscores the Company’s commitment to disciplined financial management, strategic capital allocation, and operational excellence as it navigates a complex and evolving behavioral health landscape.
Most recently, Young served as Chief Financial Officer of Elanco Animal Health Incorporated (“Elanco”), a global leader in animal health. He joined Elanco in 2018 during a pivotal period in the company’s history—as it prepared to spin off from its parent company, Eli Lilly and Company, and establish itself as an independent, publicly traded entity. In his role, Young was instrumental in building a world-class finance function from the ground up, overseeing financial planning and analysis, treasury, investor relations, tax, and internal audit. His leadership helped shape Elanco’s long-term strategic direction and supported its successful transition into a standalone company with a robust balance sheet and clear growth trajectory.
Prior to his tenure at Elanco, Young held the position of CFO at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on central nervous system disorders. During his time there, he led a comprehensive overhaul of the company’s financial operations, implementing scalable systems and processes that aligned with its commercial growth phase. Notably, Young played a key role in refining the commercial pricing strategy for ACADIA’s flagship product, pimavanserin (Nuplazid®), which was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. His strategic financial guidance helped position the company for sustainable revenue growth and enhanced shareholder value.
Academically, Young holds a Bachelor of Arts degree in Economics from Grinnell College and a Juris Doctor from the University of Michigan School of Law. His unique combination of legal and financial expertise has equipped him with a nuanced understanding of regulatory compliance, corporate governance, and strategic risk management—critical competencies in today’s highly regulated healthcare environment.
In announcing the appointment, Chris Hunter, Chief Executive Officer of Acadia Healthcare, expressed strong confidence in Young’s ability to contribute meaningfully to the Company’s strategic objectives. “On behalf of the Board and all of us at Acadia, I’m excited to welcome Todd to the team,” Hunter said. “Todd has excelled at leading finance organizations at publicly traded companies through periods of transformation and growth. His deep expertise in capital allocation, treasury management, and financial strategy aligns perfectly with our priorities as we execute a disciplined growth strategy focused on expanding access to behavioral healthcare, improving clinical outcomes, and driving operational efficiency across our national network.”
Hunter emphasized that Young’s track record of delivering strong financial and operational results—particularly in complex, regulated industries—makes him an ideal fit for Acadia’s next chapter. “We are at an inflection point where financial discipline, strategic investment, and operational rigor are more important than ever,” Hunter added. “Todd’s leadership will be instrumental in ensuring that we allocate capital wisely, optimize our cost structure, and continue to build a scalable platform that supports both patient care and long-term shareholder value.”
The CEO also took the opportunity to thank Tim Sides for his steady leadership during his interim tenure as CFO. “I thank Tim for his dedication and professionalism while serving as interim CFO,” Hunter said. “His deep institutional knowledge and operational finance expertise ensured continuity and stability during this transition period. We greatly appreciate his support in facilitating a seamless handover and look forward to continuing to benefit from his insights in his role as SVP of Operations Finance.”
Sides, who has been with Acadia since 2019, has played a pivotal role in integrating financial planning with operational execution across the Company’s expansive network of behavioral health facilities. His return to a focused operations finance role will allow him to deepen his impact on facility-level performance, cost management, and process improvement initiatives.
For his part, Todd Young expressed enthusiasm about joining Acadia at such a critical juncture. “It is an honor to join Acadia, an organization that transforms the lives of patients through its leadership in behavioral health and addiction treatment services,” Young said. “Mental health and substance use disorders affect millions of Americans, and Acadia’s commitment to providing compassionate, evidence-based care is both inspiring and urgently needed.”
Young outlined his initial priorities, which include partnering closely with Hunter and the executive leadership team to enhance financial transparency, strengthen internal controls, and embed a culture of fiscal responsibility throughout the organization. “I look forward to working closely with Chris and the rest of the leadership team to drive operational excellence and deepen financial discipline across the organization to support this vitally important mission,” he said.
The appointment comes as Acadia continues to execute on its long-term strategic plan, which emphasizes organic growth, selective acquisitions, and technological innovation to improve patient access and clinical outcomes. The Company operates a nationwide network of over 250 behavioral health facilities, offering services ranging from inpatient and outpatient care to specialized programs for adolescents, adults, and seniors.
Industry analysts view Young’s appointment as a positive signal of Acadia’s focus on governance and financial sustainability. “Bringing in a CFO with Todd’s pedigree—particularly his experience guiding companies through spin-offs and commercial scaling—suggests Acadia is positioning itself for a new phase of maturity,” said healthcare sector analyst Maria Chen of Horizon Capital Advisors. “His background in both pharmaceuticals and animal health may seem unconventional, but the core financial disciplines he’s mastered are directly transferable to behavioral health, especially as Acadia seeks to optimize its capital structure and improve margins.”
As Acadia looks ahead, the leadership team remains focused on building upon recent operational improvements, enhancing clinical quality metrics, and expanding its footprint in underserved markets. With Todd Young now at the financial helm, the Company is well-positioned to navigate macroeconomic headwinds while staying true to its core mission: delivering life-changing behavioral health care to those who need it most.
The transition is expected to be seamless, with Young assuming full CFO responsibilities on October 27, 2025. He will be based at Acadia’s corporate headquarters in Franklin, Tennessee, and will report directly to CEO Chris Hunter.
